LEONARDA-2: Lerociclib plus letrozole versus placebo plus letrozole in HR+/HER2-advanced or metastatic breast cancer

被引：0
|
作者：
Hu, Xichun
Wang, Biyun
Wang, Shusen
Tong, Zhongsheng
Sun, Tao
Li, Wei
Song, Lihua
Yan, Xi
Cheng, Ying
Qiu, Fuming
Wang, Xinshuai
Xie, Weimin
Zhao, Bing
Liu, Xinlan
Hu, Changlu
Lai, Guie
Pang, Jinke
Li, Tong
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[4] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[5] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[6] First Hosp Jilin Univ, Changchun, Peoples R China
[7] Shandong Canc Hosp & Inst, Jinan, Peoples R China
[8] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[9] Jilin Canc Hosp, Changchun, Peoples R China
[10] Zhejiang Univ, Sch Med, Affliated Hosp 2, Hangzhou, Peoples R China
[11] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[12] Guangxi Med Univ, Canc Hosp, Nanning, Peoples R China
[13] Xinjiang Med Univ, Affiliated Tumor Hosp, Urumqi, Peoples R China
[14] Ningxia Med Univ, Gen Hosp, Yinchuan, Ningxia, Peoples R China
[15] Anhui Prov Canc Hosp, Ward Med Oncol 4, Hefei, Peoples R China
[16] Jiangxi Med Coll, Affiliated Hosp 1, Ganzhou, Peoples R China
[17] Genor Biopharma Co Ltd, Shanghai, Peoples R China
[18] Genor Biopharma Co Ltd, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1052
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Ribociclib for post-menopausal women with HR+/HER2-advanced or metastatic breast cancer
    Zangardi, Mark L.
    Spring, Laura M.
    Blouin, Gayle C.
    Bardia, Aditya
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (11) : 1169 - 1176
  • [42] Palbociclib plus endocrine therapy in HR+/HER2-advanced breast cancer patients: Interim results of the PERFORM study
    Radosa, J. C.
    Fietz, T.
    Wilke, J.
    Decker, T.
    Petersen, V.
    Deryal, M.
    Knoblich, J.
    Losem, C.
    Rhein, U.
    Schoettker, B.
    Wrobel, D.
    Pfeiler, G.
    Zanucco, E.
    Buncke, J.
    Woerner, S.
    Gratzke, K.
    Adams, A.
    Glastetter, E.
    Bartsch, R.
    Lux, M. P.
    ANNALS OF ONCOLOGY, 2023, 34 : S353 - S354
  • [43] Overall survival for first-line palbociclib plus letrozole vs letrozole alone for HR+/HER2-metastatic breast cancer patients in US real-world clinical practice
    DeMichele, Angela
    Cristofanilli, Massimo
    Brufsky, Adam
    Liu, Xianchen
    Mardekian, Jack
    McRoy, Lynn
    Layman, Rachel M.
    Rugo, Hope S.
    Finn, Richard S.
    CANCER RESEARCH, 2020, 80 (04)
  • [44] MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2-advanced breast cancer: the multinational randomized phase III study
    Zhang, Qing Yuan
    Sun, Tao
    Yin, Yong Mei
    Li, Hui Ping
    Yan, Min
    Tong, Zhong Sheng
    Oppermann, Christina P.
    Liu, Yun Peng
    Costa, Romulo
    Li, Man
    Cheng, Ying
    Ouyang, Qu Chang
    Chen, Xi
    Liao, Ning
    Wu, Xin Hong
    Wang, Xiao Jia
    Feng, Ji Feng
    Hegg, Roberto
    Kanakasetty, G. B.
    Coccia-Portugal, Maria A.
    Han, Ru Bing
    Lu, Yi
    Chi, Hai Dong
    Jiang, Ze Fei
    Hu, Xi Chun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [45] WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN WOMEN WITH HR+/HER2-ADVANCED/ METASTATIC BREAST CANCER
    Wood, R.
    Mitra, D.
    DeCourcy, J.
    Iyer, S.
    VALUE IN HEALTH, 2017, 20 (05) : A123 - A123
  • [46] Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR+/HER2- Advanced Breast Cancer Enrolled in an Expanded Access Program
    Brufsky, Adam
    Mitra, Debanjali
    Davis, Keith L.
    Nagar, Saurabh P.
    McRoy, Lynn
    Cotter, Matthew J.
    Stearns, Vered
    CLINICAL BREAST CANCER, 2019, 19 (05) : 317 - +
  • [47] First-line ribociclib plus letrozole in patients with HR+, HER2-advanced breast cancer (ABC) who received prior (neo)adjuvant therapy: a subgroup analysis of the MONALEESA-2 trial
    Conte, P.
    Paluch-Shimon, S.
    Burris, H. A.
    Petrakova, K.
    Blackwell, K. L.
    Dittrich, C.
    Arteaga, C. L.
    Sutradhar, S.
    Miller, M.
    Campone, M.
    BREAST, 2017, 32 : S70 - S70
  • [48] Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
    Huang, C-S.
    Toi, M.
    Im, Y-H.
    Iwata, H.
    Sohn, J.
    Wang, H-C.
    Masuda, N.
    Im, S-A.
    Lu, Y.
    Haddad, N.
    Sakaguchi, S.
    Hurt, K.
    Neven, P.
    Llombart-Cussac, A.
    Sledge, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S1258 - S1259
  • [49] Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
    Toi, Masakazu
    Huang, Chiun-Sheng
    Im, Young-Hyuck
    Sohn, Joohyuk
    Zhang, Wei
    Sakaguchi, Sachi
    Haddad, Nadine
    van Hal, Gertjan
    Sledge Jr, George W.
    CANCER SCIENCE, 2023, 114 (01) : 221 - 226
  • [50] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Blackwell, K.
    Andre, F.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D.
    Xuan, F.
    Souami, F.
    Miller, M.
    Germa, C.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2016, 27
12345